Drug Type Small molecule drug |
Synonyms MY-008, MY008, MY008211A |
Target |
Mechanism CFB inhibitors(Complement factor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemoglobinuria, Paroxysmal | Phase 3 | CN | 07 Aug 2024 | |
Glomerulonephritis, IGA | Phase 2 | CN | 18 Nov 2024 | |
C3 glomerulopathy | IND Approval | CN | 18 Dec 2023 | |
Diabetic Nephropathies | IND Approval | CN | 18 Dec 2023 | |
Idiopathic Membranous Glomerulonephritis | IND Approval | CN | 18 Dec 2023 | |
Lupus Nephritis | IND Approval | CN | 18 Dec 2023 |
Not Applicable | - | pyomrzkdch(mofkewoycw) = n=15 of 34 patients nuecbqydae (rdcsbujazf ) View more | - | 08 Dec 2024 | |||